References
- Margolius HS. Tissue kalhkreins and kinins: regulation and roles in hypertensive and diabetic disease. Ann Rev Pharmacol Toxicol 1989; 29: 343–364
- Scicli AG, Carretero OA. Renal kallikrein-kinin system. Kidney Int 1986; 29: 120–130
- Bhoola DK, Figueroa CD, Worthy K. Bioregulation of kinins: kininogens and kininases. Pharmacol Rev 1992; 44: 1–80
- Wang C, Chao C, Chao L, Chao J. Expression of human tissue kallikrein in rat salivary gland and its secretion into circulation following adenovirus-mediated gene transfer. Immunopharmocology 1997; 36: 221–227
- Berg G, Johansen L, Nustad K. Enzymatic activity of rat submadibular gland kallikrein released into blood. Am J Physiol 1985; 249: H1134–H1142
- Roblero J, Croxatto HR, Garcia R, Corthorn J, De Vito E. Kallikrein-like activity in perfusates and urine of isolated rat kidneys. Am J Physiol 1976; 231: 1383–1389
- Vio CP, Churchill L, Rabito SF, Terragno A, Carretero OA, Terragno NA. Renal kallikrein in venous effluent of filtering and non-filtering isolated kidneys. Adv Exp Med Biol 1983; 156B: 897–905
- Nolly H, Lama MC. “Vascular kallikrein”: A kallikrein-like enzyme present in vascular tissue of rat. Clin Sci 1982; 63((Suppl. 8))249–251
- Nolly H, Scicli A, Scicli G, Carretero O A. Characterization of Kininogenase from rat vascular tissue resembling tissue kallikrein. Circ Res 1985; 56: 816–821
- Margolius HS, Horwitz D, Pisano J J, Keiser HR. Urinary kallikrein excretion in hypertensive man. Relationships to sodium intake and sodium-retaining steroids. Circ Res 1974; 3: 820–825
- Margolius HS, Geller R, De Jong W, Pisano JJ, Sjoerdsma A. Altered urinary kallikrein excretion in human hypertension. Lancet 1971; ii: 1063–1065
- Song Q, Chao J, Chao L. High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model. Clin Exper Hypertens 1996; 18: 975–993
- Blau HM, Springer ML. Muscle-mediated gene therapy. N Engl J Med 1995; 333: 1554–1556
- Tripathy SK, Goldwasser E, Lu MM, Barr E, Leiden JM. Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc Natl Acad Sci USA 1994; 91: 11557–11561
- Xiong W, Chao J, Chao L. Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension 1995; 25: 715–719
- Quantin B, Perricaudet L D, Tajbakhsh S, Mandel J L. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci USA 1992; 89: 2581–2584
- Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 1992; 90: 626–630
- Ragot T, Vincent N, Chafey P, Vigne E, Gilgenkrantz H, Couton D, Cartaud J, Briand P, Kaplan JC, Perricaudet M, Kahn A. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 1993; 361: 647–650
- Wang C, Chao L, Chao J. Direct gene delivery of human kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 1995; 95: 1710–1716
- Chao J, Zhang JJ, Lin KF, Chao L. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 1998; 9: 21–31
- Shimamoto K, Ando T, Nalcao T, Tanaka S, Sakuma M, Miyahara MA. A senstive radioimmunoassay method for urinary kmins in man. J Lab Clin Med 1987; 91: 721–728
- Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension 1997; 27: 7–13
- Nasjletti A, Colina-Chourio J, McGiff JC. Disappearance of bradykinin in the renal circulation of dogs. Effects of kininase inhibition. Circ Res 1975; 37: 59–65
- Susie H, Nasjletti A, Malik KU. Inhibition by bradykinin of the vascular action of angiotensin II in the dog kidney. J Pharmacol & Exper Therapeutics 1981; 218: 103–107
- Roman RJ, Kaldunski ML, Scicli AG, Carretero OA. Influence of kinins and angiotensin II on the regulation of papillary blood flow. Am J Physiol 1988; 255: F690–698
- Jin L, Zhang JJ, Chao L, Chao J. Gene therapy in hypertension: Adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther 1997; 8: 1753–1761
- Yayama K, Wang C, Chao L, Chao J. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 1998; 31: 1104–1110
- Murakami H, Yayama K, Chao L, Chao J. Human kallikrein gene delivery protects against genetamycin-induced nephrotoxicity in rats. Kidney Int 1998; 63: 1305–1313
- Chao J, Yang ZR, Jin L, Lin KF, Chao L. Kallikrein gene therapy in newborn and adult hypertensive rats. Can J Physiol Pharmacol 1997; 75: 750–756
- Black NJ, Kanellakis P, Bobik A. Role of angiotensin II in early cardiovascular growth and vascular amplifier development in spontaneously hypertensive rats. J Hypertens 1997; 15: 945–954
- Chen LM, Chao L, Chao J. Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. Hum Gene Ther 1997; 8: 341–347
- Budker V, Zhang G, Danko I, Wilianms P, Wolff J. The efficient expression of intravascularly delivered DNA in rat muscle. Gene Ther 1998; 5: 272–276